254 related articles for article (PubMed ID: 8318423)
1. Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.
Pedley RB; Boden JA; Boden R; Dale R; Begent RH
Br J Cancer; 1993 Jul; 68(1):69-73. PubMed ID: 8318423
[TBL] [Abstract][Full Text] [Related]
2. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy.
Behr TM; Memtsoudis S; Sharkey RM; Blumenthal RD; Dunn RM; Gratz S; Wieland E; Nebendahl K; Schmidberger H; Goldenberg DM; Becker W
Int J Cancer; 1998 Aug; 77(5):787-95. PubMed ID: 9688314
[TBL] [Abstract][Full Text] [Related]
3. Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts.
Vogel CA; Bischof-Delaloye A; Mach JP; Pèlegrin A; Hardman N; Delaloye B; Buchegger F
Br J Cancer; 1993 Oct; 68(4):684-90. PubMed ID: 8398694
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies.
Lane DM; Eagle KF; Begent RH; Hope-Stone LD; Green AJ; Casey JL; Keep PA; Kelly AM; Ledermann JA; Glaser MG
Br J Cancer; 1994 Sep; 70(3):521-5. PubMed ID: 8080740
[TBL] [Abstract][Full Text] [Related]
5. Significance of circulatory clearance of tumour-localising IgG and F(ab')2 for potential therapy studied in a CEA-producing xenograft model.
Harwood PJ; Pedley RB; Boden J; Rogers GT
Tumour Biol; 1987; 8(1):19-25. PubMed ID: 3602844
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
[TBL] [Abstract][Full Text] [Related]
7. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
Casey JL; King DJ; Chaplin LC; Haines AM; Pedley RB; Mountain A; Yarranton GT; Begent RH
Br J Cancer; 1996 Nov; 74(9):1397-405. PubMed ID: 8912535
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
[TBL] [Abstract][Full Text] [Related]
9. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
Stein R; Blumenthal R; Sharkey RM; Goldenberg DM
Cancer; 1994 Feb; 73(3 Suppl):816-23. PubMed ID: 8306265
[TBL] [Abstract][Full Text] [Related]
10. Biokinetics of a F(ab')3 iodine-131 labeled antigen binding construct (Mab 35) directed against CEA in patients with colorectal carcinoma.
Storto G; Buchegger F; Waibel R; Kuenzi G; Offord RE; Schubiger PA; Gillet M; Delaloye AB
Cancer Biother Radiopharm; 2001 Oct; 16(5):371-9. PubMed ID: 11776754
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy of human colon carcinoma by 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model.
Buchegger F; Vacca A; Carrel S; Schreyer M; Mach JP
Int J Cancer; 1988 Jan; 41(1):127-34. PubMed ID: 3335416
[TBL] [Abstract][Full Text] [Related]
12. Comparison of therapeutic efficacy and host toxicity of two different 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model.
Blumenthal RD; Sharkey RM; Kashi R; Goldenberg DM
Int J Cancer; 1989 Aug; 44(2):292-300. PubMed ID: 2759735
[TBL] [Abstract][Full Text] [Related]
13. The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.
Pedley RB; Boden JA; Boden R; Begent RH; Turner A; Haines AM; King DJ
Br J Cancer; 1994 Dec; 70(6):1126-30. PubMed ID: 7981064
[TBL] [Abstract][Full Text] [Related]
14. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.
Buchegger F; Pfister C; Fournier K; Prevel F; Schreyer M; Carrel S; Mach JP
J Clin Invest; 1989 May; 83(5):1449-56. PubMed ID: 2708519
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
[TBL] [Abstract][Full Text] [Related]
16. Iodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice.
Buchegger F; Pèlegrin A; Delaloye B; Bischof-Delaloye A; Mach JP
J Nucl Med; 1990 Jun; 31(6):1035-44. PubMed ID: 2348233
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
[TBL] [Abstract][Full Text] [Related]
18. Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer.
Ychou M; Pelegrin A; Faurous P; Robert B; Saccavini JC; Guerreau D; Rossi JF; Fabbro M; Buchegger F; Mach JP; Artus JC
Int J Cancer; 1998 Feb; 75(4):615-9. PubMed ID: 9466665
[TBL] [Abstract][Full Text] [Related]
19. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
